---
title: Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large
  B-cell lymphoma in TRANSCEND NHL 001
date: '2023-10-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37890149/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231028180731&v=2.17.9.post6+86293ac
source: Blood
description: Lisocabtagene maraleucel (liso-cel) demonstrated significant efficacy
  with a manageable safety profile as third-line or later treatment in patients with
  relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in the TRANSCEND NHL 001
  study. Primary end points were adverse events (AE), dose-limiting toxicities, and
  objective response rate (ORR) per independent review committee. Key secondary end
  points were complete response (CR) rate, duration of response (DOR), progression-free
  ...
disable_comments: true
---
Lisocabtagene maraleucel (liso-cel) demonstrated significant efficacy with a manageable safety profile as third-line or later treatment in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in the TRANSCEND NHL 001 study. Primary end points were adverse events (AE), dose-limiting toxicities, and objective response rate (ORR) per independent review committee. Key secondary end points were complete response (CR) rate, duration of response (DOR), progression-free ...